Dalle J-H, Lucchini G, Balduzzi A, Ifversen M, Jahnukainen K, Macklon K T, Ahler A, Jarisch A, Ansari M, Beohou E, Bresters D, Corbacioglu S, Dalissier A, Diaz de Heredia Rubio C, Diesch T, Gibson B, Klingebiel T, Lankester A, Lawitschka A, Moffat R, Peters C, Poirot C, Saenger N, Sedlacek P, Trigoso E, Vettenranta K, Wachowiak J, Willasch A, von Wolff M, Yaniv I, Yesilipek A, Bader P
Department of Hemato-immunology, Robert-Debre Hospital, APHP, Paris-Diderot University, Paris, France.
Department of Bone Marrow Transplant, Great Ormond Street Hospital, London, UK.
Bone Marrow Transplant. 2017 Jul;52(7):1029-1035. doi: 10.1038/bmt.2017.21. Epub 2017 Mar 13.
Nowadays, allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a well-established treatment procedure and often the only cure for many patients with malignant and non-malignant diseases. Decrease in short-term complications has substantially contributed to increased survival. Therefore long-term sequelae are reaching the focus of patient care. One of the most important risks of stem cell transplant survivors is infertility. As well as in the field of allo-HSCT also the field of reproductive medicine has achieved substantial advances to offer potential options for fertility preservation in both boys and girls. Access to these procedures as well as their financing differs significantly throughout Europe. As all European children and adolescents should have the same possibility, the Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation organised an expert meeting in September 2015. This manuscript describes the recommendations for the diagnosis and pre-emptive procedures that should be offered to all children and adolescents in Europe who have to undergo an allo-HSCT.
如今,异基因造血干细胞移植(allo-HSCT)是一种成熟的治疗方法,通常是许多恶性和非恶性疾病患者的唯一治愈方法。短期并发症的减少显著提高了生存率。因此,长期后遗症正成为患者护理的重点。干细胞移植幸存者最重要的风险之一是不孕不育。在allo-HSCT领域以及生殖医学领域都取得了重大进展,为男孩和女孩提供了生育力保存的潜在选择。在整个欧洲,获得这些治疗方法及其资金支持存在显著差异。由于所有欧洲儿童和青少年都应享有同等的可能性,欧洲血液和骨髓移植学会儿科疾病工作组于2015年9月组织了一次专家会议。本手稿描述了针对欧洲所有必须接受allo-HSCT的儿童和青少年的诊断和预防性程序的建议。